Exact Mass: 756.4061

Nostocyclopeptide A1

C37H56N8O9 (756.417)

Gambierol

C43H64O11 (756.4448)

Schidigerasaponin F2

C39H64O14 (756.4296)

Schidigerasaponin F2 is found in fruits. Schidigerasaponin F2 is a constituent of Yucca schidigera (Mojave yucca)

(25S)-Spirostane-3b,5b,6a-triol 3-[4'-rhamnosylglucoside]

C39H64O14 (756.4296)

(25S)-Spirostane-3b,5b,6a-triol 3-[4-rhamnosylglucoside] is found in onion-family vegetables. (25S)-Spirostane-3b,5b,6a-triol 3-[4-rhamnosylglucoside] is a constituent of Allium tuberosum (Chinese chives) Constituent of Allium tuberosum (Chinese chives). (25S)-Spirostane-3b,5b,6a-triol 3-[4-rhamnosylglucoside] is found in onion-family vegetables.

Tuberoside J

C39H64O14 (756.4296)

Tuberoside J is found in onion-family vegetables. Tuberoside J is a constituent of Chinese chive seeds (Allium tuberosum). Constituent of Chinese chive seeds (Allium tuberosum). Tuberoside J is found in onion-family vegetables.

Arg-Pro-Pro-Gly-Phe-Ser-Pro

C35H52N10O9 (756.3919)

PA(18:4(6Z,9Z,12Z,15Z)/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C43H65O9P (756.4366)

PA(18:4(6Z,9Z,12Z,15Z)/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:4(6Z,9Z,12Z,15Z)/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one 6Z,9Z,12Z,15Z-octadecatetraenoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/18:4(6Z,9Z,12Z,15Z))

C43H65O9P (756.4366)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/18:4(6Z,9Z,12Z,15Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of 6Z,9Z,12Z,15Z-octadecatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C43H65O9P (756.4366)

PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one 6Z,9Z,12Z,15Z-octadecatetraenoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/18:4(6Z,9Z,12Z,15Z))

C43H65O9P (756.4366)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/18:4(6Z,9Z,12Z,15Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of 6Z,9Z,12Z,15Z-octadecatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C43H65O9P (756.4366)

PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one 6Z,9Z,12Z,15Z-octadecatetraenoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/18:4(6Z,9Z,12Z,15Z))

C43H65O9P (756.4366)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/18:4(6Z,9Z,12Z,15Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of 6Z,9Z,12Z,15Z-octadecatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C43H65O9P (756.4366)

PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one 6Z,9Z,12Z,15Z-octadecatetraenoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/18:4(6Z,9Z,12Z,15Z))

C43H65O9P (756.4366)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/18:4(6Z,9Z,12Z,15Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of 6Z,9Z,12Z,15Z-octadecatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C43H65O9P (756.4366)

PA(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one 6Z,9Z,12Z,15Z-octadecatetraenoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/18:4(6Z,9Z,12Z,15Z))

C43H65O9P (756.4366)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/18:4(6Z,9Z,12Z,15Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of 6Z,9Z,12Z,15Z-octadecatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/20:5(5Z,8Z,11Z,14Z,17Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,13E)+=O(15))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/20:5(5Z,8Z,11Z,14Z,17Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/20:5(5Z,8Z,11Z,14Z,17Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/20:5(5Z,8Z,11Z,14Z,17Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/20:5(5Z,8Z,11Z,14Z,17Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/20:5(5Z,8Z,11Z,14Z,17Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Capsicoside B1

C39H64O14 (756.4296)

Capsicoside b1 is a member of the class of compounds known as steroidal saponins. Steroidal saponins are saponins in which the aglycone moiety is a steroid. The steroidal aglycone is usually a spirostane, furostane, spirosolane, solanidane, or curcubitacin derivative. Capsicoside b1 is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Capsicoside b1 can be found in a number of food items such as red bell pepper, yellow bell pepper, orange bell pepper, and pepper (c. annuum), which makes capsicoside b1 a potential biomarker for the consumption of these food products.

Aspaoligonin A

C39H64O14 (756.4296)

Linckoside K

C39H64O14 (756.4296)

Concinnasteoside A

C39H64O14 (756.4296)

Potanidine A

C41H60N2O11 (756.4197)

Linckoside M

C39H64O14 (756.4296)

Methoxyadiantifoline

C43H52N2O10 (756.3622)

(25R)-5alpha-spirostan-2alpha,3beta,12beta-triol 3-O-(O-alpha-L-rhamnopyranosyl-(1-2)-beta-D-galactopyranoside)

C39H64O14 (756.4296)

(25R)-5alpha-spirostane-3beta,6alpha-diol 3,6-di-O-beta-D-glucopyranoside|3-O-[beta-D-glucopyranosyl]-6-O-[beta-D-glucopyranosyl]chlorogenin|chlorogenin 3,6-di-O-beta-D-glucopyranoside

C39H64O14 (756.4296)

(2R,3R,4R,5R,7S,8S,9S,11E,13S,15R)-2,3,5,7,8,9,15-heptahydroxyjatropha-6(17),11-diene-14-one-7,9-diacetate-8-benzoate-2,3-bis(2-methylbutyrate)|2,3,5,7,8,9,15-heptahydroxyjatropha-6(17),11-diene-14-one 7,9-diacetate 8-benzoate 2,3-bis(2-methylbutyrate)

C41H56O13 (756.3721)

6-O-beta-D-glucopyranosyl-(1->4)-beta-D-glucopyranoside chlorogenin

C39H64O14 (756.4296)

gitogenin 3-O-beta-D-glycopyranosyl(1->3)-beta-D-glucopyranoside

C39H64O14 (756.4296)

hookerosid A

C39H64O14 (756.4296)

(25R)-1beta,2alpha-dihydroxy-5alpha-spirostan-3beta-yl O-alpha-L-rhamnopyranosyl-(1->2)-beta-D-galactopyranoside

C39H64O14 (756.4296)

18-bromooctadeca-9E,13E,17E-triene-7,15-diynoic acid xestosterol ester

C48H69BrO2 (756.4481)

C39H64O14

C39H64O14 (756.4296)

C37H56O16

C37H56O16 (756.3568)

(3beta,22xi,25R)-22-hydroxyfurost-5-ene-3,26-diyl bis(beta-D-glucopyranoside)|26-O-beta-D-glucopyranosyl-(25R)-furost-5-ene-3beta,22xi,26-triol 3-O-beta-D-glucopyranoside

C39H64O14 (756.4296)

gitogenin 3-O-beta-D-glucopyranosyl-(1->4)-O-beta-D-glucopyranoside|gitogenin bidesmoside

C39H64O14 (756.4296)

(25R)-5alpha-spirostane-3beta,6alpha-diyl bis-beta-D-glucopyranoside

C39H64O14 (756.4296)

26-O-beta-D-glucopyranosyl-5alpha-furost-20(22)-ene-1beta,4alpha,26-triol 3-O-beta-D-glucopyranoside

C39H64O14 (756.4296)

Bufotoxin

C40H60N4O10 (756.4309)

Anemarrhenasaponin III

C39H64O14 (756.4296)

(5??,25S)-Spirostan-3??,15??,23??-diol-3-O-D-glucopyranosyl-(1鈥樏傗垎2)-??-D-galactopyranoside

C39H64O14 (756.4296)

(22S)-cholest-5-ene-3beta,11alpha,16beta,22-tetrol 16-O-{2-O-acetyl-3-O-(p-methoxybenzoyl)-alpha-L-rhamnopyranoside}|(22S)-Cholest-5-ene-3??,11??,16??,22-tetrol 16-O-{2-O-acetyl-3-O-(p-methoxybenzoyl)-??-L-rhamnopyranoside}

C43H64O11 (756.4448)

Aldgamycin F

C37H56O16 (756.3568)

(22s)-1beta-[(beta-D-glucopyranosyl)oxy]-3beta,22-dihydroxycholesta-5,24-dien-16beta-yl beta-D-glucopyranoside

C39H64O14 (756.4296)

Glochidioside N

C43H64O11 (756.4448)

(25R)-Samogenin 3-O-??-D-glucopyranosyl (1鈥樏傗垎2)-??-D-galactopyranoside|(25S)-Samogenin 3-O-??-D-glucopyranosyl (1鈥樏傗垎2)-??-D-galactopyranoside

C39H64O14 (756.4296)

tetraacetyl 7-oxostigmasteryl-3-O-beta-D-glucopyranoside

C43H64O11 (756.4448)

FT-0774525

C40H60N4O10 (756.4309)

furost-5(6)-en-3beta,22alpha-diol 1beta-O-beta-D-galactopyranosyl 26-O-alpha-L-rhamnopyranoside|tropeoside A1

C39H64O14 (756.4296)

19-oxocinobufotalin 3-adipoylarginine ester

C38H52N4O12 (756.3582)

2,22-dideoxyecdysone 25-O-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranoside

C39H64O14 (756.4296)

(22R)-3beta,16beta,22,26-tetrahydroxycholest-5-ene 3-O-alpha-L-rhamnopyranosyl-(1-2)-beta-D-glucuronopyranoside

C39H64O14 (756.4296)

(3beta,5alpha,6beta,25R)-spirostane-3,5,6-triol-3-O-alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranoside

C39H64O14 (756.4296)

(22R)-3beta,16beta-di-(O-beta-D-glucopyranosyl)-22-hydroxycholest-5-en-12-one|dioscoreavilloside B

C39H64O14 (756.4296)

Rhodexin D

C37H56O16 (756.3568)

(25R)-3beta-[(beta-D-glucopyranosyl)oxy]-26-[(beta-D-glucopyranosyl)oxy]-5alpha-cholestane-6,22-dione

C39H64O14 (756.4296)

nolinofuroside C

C39H64O14 (756.4296)

3,16-di-O-beta-D-glucopyranosylcholest-5-en-23-one-3beta,7beta,16beta-triol|camassioside

C39H64O14 (756.4296)

2-O-(6-O-octanoyl-beta-D-glucopyranosyl)-6-O-(beta-D-glucopyranosyl)-1-O-octanoyl-beta-D-glucopyranose|nonioside G

C34H60O18 (756.3779)

Hookeroside A

C39H64O14 (756.4296)

(23S,25R)-6alpha-[(beta-D-glucopyranosyl)oxy]-23-hydroxy-5alpha-spirostan-3beta-yl beta-D-fucopyranoside

C39H64O14 (756.4296)

chlorogenin 6-O-beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranoside

C39H64O14 (756.4296)

linckoside I

C39H64O14 (756.4296)

(25R)-3??-Hydroxy-5??-spirostan-6??-yl O-??-D-glucopyranosyl-(1鈥樏傗垎2)-??-D-glucopyranoside

C39H64O14 (756.4296)

(25R,5alpha)-spirostan-3beta,6beta-diol 3-O-beta-D-glucopyranosyl-(1->4)-beta-D-galactopyranoside|dideglucoeruboside B

C39H64O14 (756.4296)

(25S)-Spirostane-3b,5b,6a-triol 3-[4''-rhamnosylglucoside]

C39H64O14 (756.4296)

Schidigerasaponin F2

C39H64O14 (756.4296)

Tuberoside J

C39H64O14 (756.4296)

Linkckoside I

C39H64O14 (756.4296)

Bradykinin Fragment 1-7

C35H52N10O9 (756.3919)

Bradykinin (1-7) is an amino-truncated Bradykinin peptide. Bradykinin (1-7) is a metabolite of Bradykinin, cleaved by endopeptidase. Bradykinin (1-7) is an amino-truncated Bradykinin peptide. Bradykinin (1-7) is a metabolite of Bradykinin, cleaved by endopeptidase.

Capsicoside B1

C39H64O14 (756.4296)

demethylnaphthomycin J

C43H52N2O10 (756.3622)

2-[2-[[(1S)-1-carboxy-5-[[(E)-dec-2-enoyl]-hydroxyamino]pentyl]amino]-2-oxoethyl]-4-[[(1S)-1-carboxy-5-[hydroxy-[(E)-oct-2-enoyl]amino]pentyl]amino]-2-hydroxy-4-oxobutanoic acid

C36H60N4O13 (756.4157)

PA(18:4(6Z,9Z,12Z,15Z)/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C43H65O9P (756.4366)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/18:4(6Z,9Z,12Z,15Z))

C43H65O9P (756.4366)

PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C43H65O9P (756.4366)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/18:4(6Z,9Z,12Z,15Z))

C43H65O9P (756.4366)

PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C43H65O9P (756.4366)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/18:4(6Z,9Z,12Z,15Z))

C43H65O9P (756.4366)

PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C43H65O9P (756.4366)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/18:4(6Z,9Z,12Z,15Z))

C43H65O9P (756.4366)

PA(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C43H65O9P (756.4366)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/18:4(6Z,9Z,12Z,15Z))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

C43H65O9P (756.4366)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,13E)+=O(15))

C43H65O9P (756.4366)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C43H65O9P (756.4366)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H65O9P (756.4366)

Smgdg O-24:6_6:0

C39H64O12S (756.4118)

Smgdg O-26:6_4:0

C39H64O12S (756.4118)

Smgdg O-22:6_8:0

C39H64O12S (756.4118)

Smgdg O-8:0_22:6

C39H64O12S (756.4118)

Smgdg O-28:6_2:0

C39H64O12S (756.4118)

Dgdg O-18:5_6:0

C39H64O14 (756.4296)

Dgdg O-22:5_2:0

C39H64O14 (756.4296)

Dgdg O-20:5_4:0

C39H64O14 (756.4296)

[1-heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C38H61O13P (756.385)

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C38H60O15 (756.3932)

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C38H60O15 (756.3932)

[6-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C39H64O12S (756.4118)

6-[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C43H64O11 (756.4448)

6-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C43H64O11 (756.4448)

[6-[3-dodecanoyloxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C39H64O12S (756.4118)

[3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropyl] (7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoate

C42H61O10P (756.4002)

[(2S,3S,6S)-6-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C39H64O12S (756.4118)

[(2S,3S,6S)-6-[(2S)-2-decanoyloxy-3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C39H64O12S (756.4118)

H-D-Arg-D-Pro-D-Pro-Gly-Phe-D-Ser-Pro-OH

C35H52N10O9 (756.3919)

[(2S,3S,6S)-6-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C39H64O12S (756.4118)

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C39H64O12S (756.4118)

[1-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-[(E)-tridec-8-enoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C38H61O13P (756.385)

[(2S,3S,6S)-6-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C39H64O12S (756.4118)

[(2S,3S,6S)-6-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-tetradecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C39H64O12S (756.4118)

(25S)-Spirostane-3b,5b,6a-triol 3-[4-rhamnosylglucoside]

C39H64O14 (756.4296)

[des-Phe(8), des-Arg(9)]-bradykinin

C35H52N10O9 (756.3919)

A seven-membered oligopeptide comprising Arg, Pro, Pro, Gly, Phe, Ser, and Pro residues joined in sequence by peptide bonds. It is a metabolite of bradykinin lacking the Phe residue at position 8 and the Arg residue at position 9.

DGDG O-23:6;O

C38H60O15 (756.3932)

DGDG O-24:5

C39H64O14 (756.4296)

SMGDG O-29:7;O

C38H60O13S (756.3754)

SMGDG O-30:6

C39H64O12S (756.4118)

SQDG 29:6;O

C38H60O13S (756.3754)

SQDG 30:5

C39H64O12S (756.4118)

DGMG 24:5

C39H64O14 (756.4296)

SQMG 31:5

C40H68O11S (756.4482)

DGGA 33:9;O

C42H60O12 (756.4085)

DGGA 34:8

C43H64O11 (756.4448)

PA 18:3/22:7;O

C43H65O9P (756.4366)

PA 18:4/22:6;O

C43H65O9P (756.4366)

PA 20:5/20:5;O

C43H65O9P (756.4366)

PA 40:10;O

C43H65O9P (756.4366)

HBMP 33:5;O

C39H65O12P (756.4213)

PG 20:2/13:4;O2

C39H65O12P (756.4213)

PG 20:3/13:3;O2

C39H65O12P (756.4213)

PG 20:4/12:3;O3

C38H61O13P (756.385)

PG 20:5/12:2;O3

C38H61O13P (756.385)

PG 32:7;O3

C38H61O13P (756.385)

PG 33:6;O2

C39H65O12P (756.4213)

PI O-18:0/8:2;O3

C35H65O15P (756.4061)

PI O-18:0/9:1;O2

C36H69O14P (756.4425)

PI O-26:2;O3

C35H65O15P (756.4061)

PI O-27:1;O2

C36H69O14P (756.4425)

PI 18:0/7:2;O3

C34H61O16P (756.3697)

PI 18:0/8:1;O2

C35H65O15P (756.4061)

PI 22:0/4:1;O2

C35H65O15P (756.4061)

PI 25:2;O3

C34H61O16P (756.3697)

PI 26:1;O2

C35H65O15P (756.4061)

PEth 38:10;O

C43H65O9P (756.4366)

PM 39:10;O

C43H65O9P (756.4366)

(1r,2s,3as,3bs,9ar,9bs,11as)-2-{[(2r,3r,4s,5s,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-1-[(2s,3s,6s)-3,7-dihydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C39H64O14 (756.4296)

(2r,3r,4s,5r,6r)-2-{[(1s,2s,4s,6r,7s,8r,9s,12s,13r,14r,16r)-6,16-dihydroxy-7,9,13-trimethyl-6-[(3r)-3-methyl-4-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}butyl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,4r,5s,6r)-2-hydroxy-2-[(2s,3r,4s)-3-hydroxy-4-[(2r,3s,4e,6e,9s,10s,11r,12e,14e)-10-hydroxy-3-methoxy-7,9,11,13,15-pentamethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-6-isopropyl-5-methyloxan-4-yl (2e)-3-(2,5-dioxofuran-3-yl)prop-2-enoate

C42H60O12 (756.4085)

(2s,3s,4s,5r,6r)-2-{[(1s,2r,3as,3br,7s,9as,9bs,10r,11ar)-7,10-dihydroxy-1-[(2s,3r)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-3-(acetyloxy)-5-hydroxy-6-methyloxan-4-yl 4-methoxybenzoate

C43H64O11 (756.4448)

2-{[3,5-dihydroxy-6-(hydroxymethyl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-1-(3,7-dihydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one

C39H64O14 (756.4296)

2-{[4,5-dihydroxy-2-(hydroxymethyl)-6-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-18',19'-dioloxy}oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3r,4s,5s,6r)-2-{[(1s,2s,4s,6s,7s,8r,9s,12s,13r,16s)-6-hydroxy-7,9,13-trimethyl-6-[(3r)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-16-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13's,15's,16'r,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

2-{[4,5-dihydroxy-6-(hydroxymethyl)-2-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-8'-oloxy}oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

2-{[4,5-dihydroxy-6-(hydroxymethyl)-2-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-10'-oloxy}oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

2-[(6,16-dihydroxy-7,9,13-trimethyl-6-{3-methyl-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]butyl}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3r,4s,5r,6r)-2-{[(1s,2s,4s,6s,7s,8r,9s,12s,13r,14r,16r)-6,16-dihydroxy-7,9,13-trimethyl-6-[(3r)-3-methyl-4-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}butyl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

7-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-1-[5-({[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-methylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C39H64O14 (756.4296)

(2s,3r,4s,5s,6r)-2-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13's,15'r,16'r,18's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

1,4-bis{[(1s,3s,4r)-3-hydroxy-4-(2-hydroxyethyl)-4-(hydroxymethyl)cyclohexyl]methyl} (2e,3e)-2-[(3,4-dimethoxyphenyl)methylidene]-3-[(4-methoxyphenyl)methylidene]butanedioate

C41H56O13 (756.3721)

(2r,3r,4r,5r,7s,8s,9s,11e,13s,15r)-2,3,5,7,8,9,15-heptahydroxyjatropha-6(17),11-diene-14-one-7,9-diacetate-8-benzoate-2,3-bis(2-me-thylbutyrate)

C41H56O13 (756.3721)

{"Ingredient_id": "HBIN006420","Ingredient_name": "(2r,3r,4r,5r,7s,8s,9s,11e,13s,15r)-2,3,5,7,8,9,15-heptahydroxyjatropha-6(17),11-diene-14-one-7,9-diacetate-8-benzoate-2,3-bis(2-me-thylbutyrate)","Alias": "NA","Ingredient_formula": "C41H56O13","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "9394","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

agave cantala compound 1

C39H64O14 (756.4296)

{"Ingredient_id": "HBIN014841","Ingredient_name": "agave cantala compound 1","Alias": "NA","Ingredient_formula": "C39H64O14","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "721","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

agave cantala saponin 1

C39H64O14 (756.4296)

{"Ingredient_id": "HBIN014843","Ingredient_name": "agave cantala saponin 1","Alias": "NA","Ingredient_formula": "C39H64O14","Ingredient_Smile": "CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CC(C(C6)OC7C(C(C(C(O7)CO)O)O)OC8C(C(C(C(O8)CO)O)O)O)O)C)C)C)OC1","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "723","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

AnemarrhenasapininIII

C39H64O14 (756.4296)

{"Ingredient_id": "HBIN016048","Ingredient_name": "AnemarrhenasapininIII","Alias": "NA","Ingredient_formula": "C39H64O14","Ingredient_Smile": "CC1CCC2(C(C3C(O2)C(C4C3(CCC5C4CCC6C5(CCC(C6)OC7C(C(C(C(O7)CO)O)O)OC8C(C(C(C(O8)CO)O)O)O)C)C)O)C)OC1","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "40126","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13's,15'r,16'r,18's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy]oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1'r,2r,2's,4's,5s,7's,8'r,9's,12's,13's,15's,16'r,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3r,4r,5r,6s)-2-[(2r)-4-[(1s,2s,4s,6s,7s,8r,9s,12s,13r,14r,16r)-6,16-dihydroxy-7,9,13-trimethyl-14-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-6-yl]-2-methylbutoxy]-6-methyloxane-3,4,5-triol

C39H64O14 (756.4296)

(1r,2r,3r,3as,3bs,5r,7s,9ar,9br,11ar)-7-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-9a,11a-dimethyl-1-[(2r,6s)-6-methyl-5-methylidene-7-{[(2r,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}heptan-2-yl]-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C39H64O14 (756.4296)

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,16's,18's,19's)-5,7',9',13'-tetramethyl-16'-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy]oxane-3,4,5-triol

C39H64O14 (756.4296)

(2r)-2-[(1r,2s,3as,3bs,4r,7s,9ar,9bs,11as)-4-hydroxy-9a,11a-dimethyl-2,7-bis({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylheptan-4-one

C39H64O14 (756.4296)

nonioside g

C34H60O18 (756.3779)

(2r,3r,4s,5s,6r)-2-{[(1r,2s,3as,3bs,7r,9r,9ar,9bs)-7-hydroxy-1-[(2s,3s)-3-hydroxy-6-methylhept-5-en-2-yl]-9a,11a-dimethyl-9-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1'r,2r,2's,3'r,4'r,5s,7's,8'r,9's,12's,13's,16's,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-3'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3r,4s,5r,6r)-2-{[(1s,2s,4s,6r,7s,8r,9s,12s,13r,14r,16r)-6,16-dihydroxy-7,9,13-trimethyl-6-[(3s)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl]oxy}-6-methyloxane-3,4,5-triol

C39H64O14 (756.4296)

7-hydroxy-9a,11a-dimethyl-1-(6-methyl-4-oxoheptan-2-yl)-2-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-9-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-tetradecahydrocyclopenta[a]phenanthren-4-one

C39H64O14 (756.4296)

2-{[4,5-dihydroxy-6-(hydroxymethyl)-2-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-16'-oloxy}oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

2-[(8-{[(1r,2s,3as,5ar,7s,9as,11ar)-2-(acetyloxy)-3a-hydroxy-9a,11a-dimethyl-1-(2-oxopyran-4-yl)-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-8-oxooctylidene)amino]-5-carbamimidamidopentanoic acid

C40H60N4O10 (756.4309)

2-hydroxy-2-[3-hydroxy-4-(10-hydroxy-3-methoxy-7,9,11,13,15-pentamethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl)pentan-2-yl]-6-isopropyl-5-methyloxan-4-yl 3-(2,5-dioxofuran-3-yl)prop-2-enoate

C42H60O12 (756.4085)

2-(hydroxymethyl)-6-(5,7',9',13'-tetramethyl-16'-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s)-2-[(6-{[(1r,2s,4r,5r,6r,7r,10s,11s,14s,16s)-5-(acetyloxy)-11-formyl-16-hydroxy-7-methyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl]oxy}-1-hydroxy-6-oxohexylidene)amino]-5-carbamimidamidopentanoic acid

C38H52N4O12 (756.3582)

(1r,2r,3s,6e,8s,9r,10r,12r,14e,16r)-12-hydroxy-2-({[(2r,3s,4r,5r,6s)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-9-{[(4s,5r,6r,7r,9r)-6-hydroxy-4,9-dimethyl-2-oxo-1,3,8-trioxaspiro[4.5]decan-7-yl]oxy}-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-6,14-diene-5,13-dione

C37H56O16 (756.3568)

(1r,2s,3as,3bs,5ar,7r,9r,9as,9bs,11as)-7-hydroxy-9a,11a-dimethyl-1-[(2r)-6-methyl-4-oxoheptan-2-yl]-2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-9-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-4-one

C39H64O14 (756.4296)

(2s,3r,4r,5r,6s)-2-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1's,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,16's,18's,19's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-18',19'-dioloxy]oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3r,4r,5r,6s)-2-[(2r)-4-[(1s,2s,4s,6r,7s,8r,9s,12s,13r,14r,16r)-6,16-dihydroxy-7,9,13-trimethyl-14-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-6-yl]-2-methylbutoxy]-6-methyloxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3r,3as,4r,6s,7s,8s,12s,13ar)-6,8-bis(acetyloxy)-4,13a-dihydroxy-2,9,9,12-tetramethyl-2,3-bis({[(2r)-2-methylbutanoyl]oxy})-5-methylidene-13-oxo-1h,3h,3ah,4h,6h,7h,8h,12h-cyclopenta[12]annulen-7-yl benzoate

C41H56O13 (756.3721)

(2r,3r,4s,5s,6r)-2-{[(1s,2s,4s,6s,7s,8r,9s,12s,13r,16s)-6-hydroxy-7,9,13-trimethyl-6-[(3s)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-16-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

12-hydroxy-2-{[(5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl)oxy]methyl}-9-({6-hydroxy-4,9-dimethyl-2-oxo-1,3,8-trioxaspiro[4.5]decan-7-yl}oxy)-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-6,14-diene-5,13-dione

C37H56O16 (756.3568)

1,4-bis{[(1s,3s,4r)-3-hydroxy-4-(2-hydroxyethyl)-4-(hydroxymethyl)cyclohexyl]methyl} (2e)-2-[(3,4-dimethoxyphenyl)methylidene]-3-[(4-methoxyphenyl)methylidene]butanedioate

C41H56O13 (756.3721)

2-{[4,5-dihydroxy-2-(hydroxymethyl)-6-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-19'-oloxy}oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

2-[3-benzyl-1,4,7,10,13,16-hexahydroxy-15-(hydroxymethyl)-6,18-diisopropyl-19-oxo-12-(sec-butyl)-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-9-yl]ethanimidic acid

C37H56N8O9 (756.417)

2-[(3s,6s,9s,12s,15s,18s,23as)-3-benzyl-12-[(2s)-butan-2-yl]-1,4,7,10,13,16-hexahydroxy-15-(hydroxymethyl)-6,18-diisopropyl-19-oxo-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-9-yl]ethanimidic acid

C37H56N8O9 (756.417)

3-[1,7,10,13,16-pentahydroxy-18-(hydroxymethyl)-6-[(4-hydroxyphenyl)methyl]-22-methyl-3-(2-methylpropyl)-19-oxo-15-(sec-butyl)-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-12-yl]propanimidic acid

C37H56N8O9 (756.417)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13's,15's,16'r,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

2-[(8-{[2-(acetyloxy)-3a-hydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-8-oxooctylidene)amino]-5-carbamimidamidopentanoic acid

C40H60N4O10 (756.4309)

6,8-bis(acetyloxy)-4,13a-dihydroxy-2,9,9,12-tetramethyl-2,3-bis[(2-methylbutanoyl)oxy]-5-methylidene-13-oxo-1h,3h,3ah,4h,6h,7h,8h,12h-cyclopenta[12]annulen-7-yl benzoate

C41H56O13 (756.3721)

(1r,2s,3as,3bs,5ar,7r,9r,9as,9bs,11as)-7-hydroxy-9a,11a-dimethyl-1-[(2r)-6-methyl-4-oxoheptan-2-yl]-2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-9-{[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-4-one

C39H64O14 (756.4296)

(2r,3r,4s,5s,6r)-2-[(1'r,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,16's,18's,19's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-19'-oloxy]-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

[(2r,3r,4s,5r,6r)-6-{[(1r,3as,3bs,7s,9ar,9bs,11ar)-1-[(2r,3e,5s)-5-ethyl-6-methylhept-3-en-2-yl]-9a,11a-dimethyl-4-oxo-1h,2h,3h,3ah,3bh,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-tris(acetyloxy)oxan-2-yl]methyl acetate

C43H64O11 (756.4448)

2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy}oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(6z,14z)-12-hydroxy-2-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-9-{[(4s,5r,6r,7s,9r)-6-hydroxy-4,9-dimethyl-2-oxo-1,3,8-trioxaspiro[4.5]decan-7-yl]oxy}-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-6,14-diene-5,13-dione

C37H56O16 (756.3568)

2-(hydroxymethyl)-6-{5,7',9',13'-tetramethyl-16'-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-3-oloxy}oxane-3,4,5-triol

C39H64O14 (756.4296)

7-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-9a,11a-dimethyl-1-{6-methyl-5-methylidene-7-[(3,4,5-trihydroxyoxan-2-yl)oxy]heptan-2-yl}-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C39H64O14 (756.4296)

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's,18's,19's)-5,7',9',13'-tetramethyl-16'-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy]oxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3r,4s,5s,6r)-2-{[(1r,2s,3as,3bs,7r,9r,9ar,9bs,11as)-7-hydroxy-1-[(2s,3s)-3-hydroxy-6-methylhept-5-en-2-yl]-9a,11a-dimethyl-9-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3r,4r,5s,6s)-2-{[(1s,2s,3as,3bs,7s,9ar,9bs,10r,11as)-7,10-dihydroxy-1-[(2s,3s)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-3-(acetyloxy)-5-hydroxy-6-methyloxan-4-yl 4-methoxybenzoate

C43H64O11 (756.4448)

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's,17's,18'r)-5,7',9',13'-tetramethyl-16'-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]oxy]oxane-3,4,5-triol

C39H64O14 (756.4296)

2-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-19'-oloxy}-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s)-2-[(8-{[(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-2-(acetyloxy)-3a-hydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-8-oxooctylidene)amino]-5-carbamimidamidopentanoic acid

C40H60N4O10 (756.4309)

2-({3-carboxy-3-[({1-carboxy-5-[(2e)-n-hydroxydec-2-enamido]pentyl}-c-hydroxycarbonimidoyl)methyl]-1,3-dihydroxypropylidene}amino)-6-[(2e)-n-hydroxyoct-2-enamido]hexanoic acid

C36H60N4O13 (756.4157)

(3r,4as,5s,6as,6bs,8as,9r,10s,12as,12br,14br)-3-hydroxy-4a,9-bis(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicen-5-yl benzoate

C43H64O11 (756.4448)

2-[4-(14-hydroxy-7,9,13-trimethyl-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-6-en-6-yl)-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1'r,2r,2's,4's,5s,7's,8'r,9's,12's,13's,15's,16's,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(1r,2r,3r,3as,3bs,5r,7s,9ar,9br,11ar)-7-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-1-[(2r,3e,5r)-5-({[(2r,3r,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-methylhept-3-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C39H64O14 (756.4296)

2-{[7-hydroxy-1-(3-hydroxy-6-methylhept-5-en-2-yl)-9a,11a-dimethyl-9-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's,18's,19'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-19'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3r,4s,5s,6r)-2-[(2r)-4-[(1s,2s,4s,8s,9s,12s,13s,14r,16s,18s)-14-hydroxy-7,9,13-trimethyl-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-6-en-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1's,2r,2's,4's,5r,7's,8'r,9's,10'r,12's,13's,16's,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-10'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s,3r,4r,5r,6s)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1'r,2r,2's,4's,5r,7's,8'r,9's,10'r,12's,13's,15'r,16'r,18's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-10',15'-dioloxy]oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C39H64O14 (756.4296)

2-{[4,5-dihydroxy-6-(hydroxymethyl)-2-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy}oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's,18's,19's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-16'-oloxy]oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3r,4s,5r,6r)-2-{[(1s,2s,4s,6r,7s,8r,9s,12s,13r,14r,16r)-6,16-dihydroxy-7,9,13-trimethyl-6-(3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl)-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl]oxy}-6-methyloxane-3,4,5-triol

C39H64O14 (756.4296)

6-{[1-(3,7-dihydroxy-6-methylheptan-2-yl)-2-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4-dihydroxy-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxane-2-carboxylic acid

C39H64O14 (756.4296)

2-{[6-hydroxy-7,9,13-trimethyl-6-(3-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl)-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-16-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

2-{[4,5-dihydroxy-6-(hydroxymethyl)-2-[5-(hydroxymethyl)-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy]oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C39H64O14 (756.4296)

2-{[4,5-dihydroxy-6-(hydroxymethyl)-2-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-3'-oloxy}oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s,3s,4s,5r,6r)-6-{[(1r,2s,3as,3bs,7s,9ar,9bs,11as)-1-[(2s,3r,6r)-3,7-dihydroxy-6-methylheptan-2-yl]-2-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4-dihydroxy-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxane-2-carboxylic acid

C39H64O14 (756.4296)

11-(hepta-1,3,6-trien-1-yl)-29-(3-hydroxypropyl)-3,5,10,24,26-pentamethyl-2,6,12,16,21,25,30,34-octaoxaoctacyclo[18.16.0.0³,¹⁷.0⁵,¹⁵.0⁷,¹³.0²²,³⁵.0²⁴,³³.0²⁶,³¹]hexatriacont-8-ene-10,27-diol

C43H64O11 (756.4448)

2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-16'-oloxy}oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2s,3r,4r,5r,6s)-2-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1'r,2r,2's,4's,5s,7's,8'r,9's,12's,13's,15'r,16'r,18's)-5-(hydroxymethyl)-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy]oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C39H64O14 (756.4296)

(2s,3r,4's,5r,6s,8'r,10'e,13's,14'e,16'e,20'r,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,21',24'-trihydroxy-5,11',13',22'-tetramethyl-12'-[(2-methylpropanoyl)oxy]-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-4-yl 2-methylpropanoate

C42H60O12 (756.4085)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1'r,2r,2's,3'r,4'r,5s,7's,8'r,9's,12's,13's,16'r,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-3'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

[3,4,5-tris(acetyloxy)-6-{[1-(5-ethyl-6-methylhept-3-en-2-yl)-9a,11a-dimethyl-4-oxo-1h,2h,3h,3ah,3bh,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}oxan-2-yl]methyl acetate

C43H64O11 (756.4448)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13's,15'r,16'r,18's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(1'r,2s,2's,3s,4's,5r,7's,8'r,9's,12's,13'r,16's,18's,19's)-5,7',9',13'-tetramethyl-16'-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-3-oloxy]oxane-3,4,5-triol

C39H64O14 (756.4296)

2-{[6,16-dihydroxy-7,9,13-trimethyl-6-(3-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl)-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl]oxy}-6-methyloxane-3,4,5-triol

C39H64O14 (756.4296)

(6-{[4,5-dihydroxy-2-(octanoyloxy)-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl)methyl octanoate

C34H60O18 (756.3779)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1'r,2r,2's,4's,5s,7's,8's,9's,12's,13's,16's,18'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-8'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

3-hydroxy-4a,9-bis(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicen-5-yl benzoate

C43H64O11 (756.4448)

(1r,3s,5r,7s,10r,11s,13r,15s,17r,20s,22r,24s,26r,27r,29r,31s,33r,35s)-11-[(1z,3z)-hepta-1,3,6-trien-1-yl]-29-(3-hydroxypropyl)-3,5,10,24,26-pentamethyl-2,6,12,16,21,25,30,34-octaoxaoctacyclo[18.16.0.0³,¹⁷.0⁵,¹⁵.0⁷,¹³.0²²,³⁵.0²⁴,³³.0²⁶,³¹]hexatriacont-8-ene-10,27-diol

C43H64O11 (756.4448)

3-(acetyloxy)-2-{[7,10-dihydroxy-1-(3-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-5-hydroxy-6-methyloxan-4-yl 4-methoxybenzoate

C43H64O11 (756.4448)

(2r,3r,4s,5s,6r)-2-{[(1s,2s,4s,6r,7s,8r,9s,12s,13r,16s)-6-hydroxy-7,9,13-trimethyl-6-[(3r)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-16-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

(2r,3r,4r,5s,6s)-2-{[(1r,2s,3as,3bs,7s,9ar,9bs,10r,11as)-7,10-dihydroxy-1-[(2s,3s)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-3-(acetyloxy)-5-hydroxy-6-methyloxan-4-yl 4-methoxybenzoate

C43H64O11 (756.4448)

2-[4-hydroxy-9a,11a-dimethyl-2,7-bis({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylheptan-4-one

C39H64O14 (756.4296)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's,18's,19's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-16'-oloxy]oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

2-{[4,5-dihydroxy-6-(hydroxymethyl)-2-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-10',15'-dioloxy}oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C39H64O14 (756.4296)

2-{[4,5-dihydroxy-2-(hydroxymethyl)-6-{5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-15'-oloxy}oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C39H64O14 (756.4296)

2-[(6-{[5-(acetyloxy)-11-formyl-16-hydroxy-7-methyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl]oxy}-1-hydroxy-6-oxohexylidene)amino]-5-carbamimidamidopentanoic acid

C38H52N4O12 (756.3582)